PYY as an Obesity Drug: Potential, Challenges, and the Path to Clinical Development

PYY3-36 potently reduces appetite through Y2 receptor-mediated hypothalamic signaling, but clinical development faces challenges including nausea at therapeutic doses and limited duration of effect.

Renshaw, D et al.·Current drug targets·2005·Moderate EvidenceReview
RPEP-01079ReviewModerate Evidence2005RETHINKTHC RESEARCH DATABASErethinkthc.com/research

Quick Facts

Study Type
Review
Evidence
Moderate Evidence
Sample
Not reported

What This Study Found

PYY3-36 reduces food intake through peripheral Y2 receptor-mediated hypothalamic appetite suppression, with clinical development challenges including dose-limiting nausea, route-dependent efficacy, and need for sustained-release formulations.

Key Numbers

How They Did This

review study on neuropeptides, weight-loss.

Why This Research Matters

Relevant for neuropeptides, weight-loss.

The Bigger Picture

Advances peptide/biomarker research.

What This Study Doesn't Tell Us

See abstract.

Questions This Raises

  • ?Further research needed.
  • ?Clinical translation to evaluate.

Trust & Context

Key Stat:
Key finding PYY3-36 reduces food intake through peripheral Y2 receptor-mediated hypothalamic appetite suppression, with clinical development challenges including
Evidence Grade:
moderate evidence.
Study Age:
Published in 2005.
Original Title:
Peptide YY: a potential therapy for obesity.
Published In:
Current drug targets, 6(2), 171-9 (2005)
Database ID:
RPEP-01079

Evidence Hierarchy

Meta-Analysis / Systematic Review
Randomized Controlled Trial
Cohort / Case-Control
Cross-Sectional / ObservationalSnapshot without intervening
This study
Case Report / Animal Study

Summarizes existing research on a topic.

What do these levels mean? →

Frequently Asked Questions

What was studied?

PYY as an Obesity Drug: Potential, Challenges, and the Path to Clinical Development

What was found?

PYY3-36 potently reduces appetite through Y2 receptor-mediated hypothalamic signaling, but clinical development faces challenges including nausea at therapeutic doses and limited duration of effect.

Read More on RethinkPeptides

Cite This Study

RPEP-01079·https://rethinkpeptides.com/research/RPEP-01079

APA

Renshaw, D; Batterham, R L. (2005). Peptide YY: a potential therapy for obesity.. Current drug targets, 6(2), 171-9.

MLA

Renshaw, D, et al. "Peptide YY: a potential therapy for obesity.." Current drug targets, 2005.

RethinkPeptides

RethinkPeptides Research Database. "Peptide YY: a potential therapy for obesity." RPEP-01079. Retrieved from https://rethinkpeptides.com/research/renshaw-2005-peptide-yy-a-potential

Access the Original Study

Study data sourced from PubMed, a service of the U.S. National Library of Medicine, National Institutes of Health.

This study breakdown was produced by the RethinkPeptides research team. We analyze and report published research findings without making health recommendations. All interpretations are based solely on the published abstract and study data.